A 32-year-old woman with a family history of early-onset breast and ovarian cancer is found to carry a BRCA1 mutation. She is counseled regarding risk reduction strategies. Which drug is the preferred choice for chemoprevention in BRCA1 mutation carriers to reduce breast cancer risk?

Explanation

## Chemoprevention in BRCA1 Mutation Carriers **Key Point:** Tamoxifen is the gold-standard chemopreventive agent for BRCA1/BRCA2 mutation carriers at high risk of breast cancer, reducing incidence by approximately 50%. ### Mechanism of Action Tamoxifen acts as a selective estrogen receptor modulator (SERM), blocking estrogen signaling in breast tissue while maintaining estrogenic effects in bone and cardiovascular tissue. ### Evidence Base The NSABP P-1 trial demonstrated that tamoxifen reduces breast cancer risk in high-risk women, including BRCA carriers. It is FDA-approved for breast cancer prevention in women at high risk. ### Clinical Considerations | Feature | Tamoxifen | Aromatase Inhibitors (Letrozole, Anastrozole) | |---------|-----------|----------------------------------------------| | **Mechanism** | SERM (ER antagonist in breast) | Blocks estrogen synthesis | | **Efficacy in BRCA** | Proven (50% risk reduction) | Less evidence in BRCA carriers | | **Menopausal status** | Both pre- and postmenopausal | Postmenopausal only | | **Bone effects** | Protective | Detrimental | | **VTE risk** | Increased | Lower | | **Endometrial cancer** | Increased risk (~2×) | No increase | **High-Yield:** Tamoxifen is the only chemopreventive agent with robust evidence in BRCA mutation carriers across both pre- and postmenopausal women. **Clinical Pearl:** Aromatase inhibitors may be considered in postmenopausal BRCA carriers, but tamoxifen remains first-line due to superior evidence base and ability to use in premenopausal women. **Warning:** Do not confuse chemoprevention with therapeutic treatment — aromatase inhibitors are used in treatment of established ER+ breast cancer but lack evidence for prevention in BRCA carriers.